Drugs Containing Excipient (Inactive Ingredient) PULLULAN

Branded drugs containing PULLULAN excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aquestive Therapeutics	EXSERVAN	riluzole	10094-350	PULLULAN
Mitsubishi Tanabe Pharma America Inc	EXSERVAN	riluzole	70510-2201	PULLULAN

Generic drugs containing PULLULAN excipient

Company	Ingredient	NDC	Excipient
Walgreens Company	loratadine	0363-9955	PULLULAN
Aquestive Therapeutics	riluzole	10094-350	PULLULAN
Dr Reddy's Laboratories Inc	loratadine	43598-707	PULLULAN

Pullulan Excipient Market Dynamics and Financial Trajectory

Last updated: September 14, 2026

Pullulan is a fermentation-derived polysaccharide used in hard capsules, oral films, tablet coatings, microencapsulation, and controlled-release delivery systems. The market is small relative to gelatin, hydroxypropyl methylcellulose (HPMC), and synthetic film-forming polymers, but it has attractive growth characteristics: plant-based positioning, low oxygen permeability, strong film formation, and compatibility with vegetarian dosage forms.

Public companies do not separately report pullulan revenue. Published market studies generally place the total pullulan market, including food, pharmaceutical, nutraceutical, and cosmetic uses, in the low hundreds of millions of dollars globally by the early 2030s. Pharmaceutical and nutraceutical applications account for a minority of total volume but a higher share of value because of qualification, purity, documentation, and formulation requirements.[1]

What is pullulan and why is it used as a pharmaceutical excipient?

Pullulan is a neutral, water-soluble polysaccharide produced by fermentation of the microorganism Aureobasidium pullulans. Its technical value comes from film-forming performance, low oxygen permeability, low toxicity, and compatibility with oral delivery systems.

Property	Commercial relevance
Film formation	Supports capsules, oral strips, coatings, and edible films
Low oxygen permeability	Helps protect oxygen-sensitive ingredients
Water solubility	Enables rapid dissolution and oral-film applications
Non-animal origin	Supports vegetarian, vegan, halal, and kosher positioning
Neutral taste and odor	Improves acceptability in oral dosage forms
Fermentation production	Reduces dependence on animal-derived raw materials
Low molecular-weight control	Allows adjustment of viscosity and dissolution behavior

Pullulan is used most visibly in hard capsules. Pullulan capsules can provide a plant-derived alternative to gelatin and may offer different oxygen and moisture-barrier characteristics from HPMC capsules. Pharmaceutical developers also use pullulan in fast-dissolving oral films, mucoadhesive films, coated particles, and encapsulated active ingredients.

The main technical limitation is cost. Pullulan is generally more expensive than commodity gelatin and competes with HPMC, starch derivatives, maltodextrin, polyvinyl alcohol, and synthetic film-forming polymers.

How large is the pullulan excipient market?

The market is difficult to size because commercial reports use inconsistent boundaries. Some include all food and cosmetic applications, while others count only pharmaceutical-grade material or capsule production.

Market measure	Current commercial interpretation
Total pullulan market	Niche specialty-material market, generally estimated in the tens to low hundreds of millions of dollars
Pharmaceutical and nutraceutical share	Smaller than food use by volume, but higher value per kilogram
Growth profile	Mid- to high-single-digit annual growth in most published forecasts
Main volume driver	Food and nutraceutical film, coating, and capsule applications
Main value driver	Pharmaceutical-grade capsules, oral films, and specialty delivery systems
Revenue disclosure	Not separately reported by major public suppliers

Published forecasts typically project sustained growth through 2030, with estimates varying substantially by definition and geography.[1] The most defensible financial conclusion is directional rather than a single market number: pullulan should expand faster than mature commodity excipients, but its absolute revenue base remains small.

What is driving pullulan market growth?

Vegetarian and non-animal capsule demand

The strongest commercial driver is demand for non-gelatin capsules. Pharmaceutical and nutraceutical companies use pullulan and HPMC to avoid animal-derived materials and to support vegan, halal, and kosher product claims.

Pullulan has an advantage in applications where oxygen protection is important. This can support higher-value positioning for probiotics, oxygen-sensitive supplements, botanical products, and selected pharmaceutical formulations.

Oral thin films and fast-dissolving dosage forms

Pullulan produces clear, flexible films and can be processed with active pharmaceutical ingredients, sweeteners, plasticizers, and permeation enhancers. Oral films are being developed for small-molecule drugs, nutraceuticals, pediatric products, and products intended for patients with difficulty swallowing.

The commercial opportunity is larger in development pipelines than in current sales. Oral films remain a specialized dosage form, and many products do not progress beyond formulation or regional commercialization.

Clean-label and plant-based formulation trends

Food and nutraceutical manufacturers use pullulan as a film former, coating material, binder, and encapsulation polymer. These applications support manufacturing scale and help suppliers spread fermentation and purification costs across several end markets.

Encapsulation and barrier performance

Pullulan films can provide useful barriers against oxygen and selected environmental stresses. This creates opportunities in microencapsulation, probiotic stabilization, active-ingredient protection, and controlled-release systems. These applications normally require more formulation work than standard capsule production but can produce higher margins.

Who are the leading pullulan manufacturers?

The supply base is concentrated among specialist fermentation and polysaccharide producers. Hayashibara, a Nagase Group company, is the best-known commercial supplier associated with pharmaceutical and food-grade pullulan. Its product portfolio includes pullulan grades used in capsules, films, coatings, and related applications.[2]

Supplier or supplier group	Market position	Key commercial attributes
Hayashibara, Nagase Group	Major established producer	Pharmaceutical and food grades, technical support, global qualification capability
Chinese fermentation manufacturers	Cost-competitive supply	Broad grade availability, export growth, variable qualification depth
Regional specialty excipient suppliers	Distribution and formulation support	Local regulatory documentation and customer service
Capsule manufacturers	Downstream demand and integration	Convert pullulan into finished capsule systems

Supplier qualification is a material barrier. Drug manufacturers typically require consistent molecular weight, viscosity, microbial limits, residual solvent control, heavy-metal testing, batch traceability, change-control procedures, and long-term supply assurance.

The market is therefore unlikely to behave like a fully commoditized polymer market in the near term. Low-cost material can enter the market, but it may not quickly displace a qualified supplier in an approved pharmaceutical product.

What are the main cost and margin drivers for pullulan?

Pullulan is produced through fermentation, followed by recovery, purification, drying, milling, and quality testing. Its cost structure is more complex than that of many commodity excipients.

Cost driver	Effect on financial performance
Fermentation yield	Determines plant productivity and raw-material efficiency
Fermentation energy	Influences conversion cost and carbon footprint
Purification	Raises cost for pharmaceutical-grade material
Drying and milling	Affects energy use, particle properties, and batch consistency
Microbial and endotoxin controls	Increases testing and release costs
Regulatory documentation	Raises fixed costs but supports premium pricing
Scale utilization	Strongly affects gross margin in a niche market
Customer qualification	Slows switching and supports recurring revenue

The financial trajectory depends on whether suppliers can move customers from generic pullulan powder to qualified grades and integrated formulation support. Higher-margin opportunities include capsule-grade material, customized viscosity grades, film-forming systems, and co-development services.

Margin pressure will increase if Chinese producers expand capacity faster than demand. The most vulnerable segment is food-grade and lower-specification pullulan, where buyers are more price-sensitive and switching costs are lower.

What is the FDA regulatory status of pullulan as an excipient?

Pullulan does not have a drug-like approval that automatically authorizes use in every pharmaceutical product. Its regulatory status depends on the application, grade, route of administration, product composition, and jurisdiction.

In the United States, manufacturers must establish that the excipient is suitable for the intended use in the finished drug product. FDA’s Inactive Ingredient Database is an important reference for prior use in approved drug products, but an excipient’s presence in the database does not eliminate the need for product-specific quality and regulatory assessment.[3]

Pullulan has a longer history in food and nutraceutical applications than in mainstream prescription drugs. In Europe, pullulan is recognized as food additive E1204, and the European Food Safety Authority has evaluated its safety as a food additive.[4] Food authorization does not by itself establish acceptance for a pharmaceutical route or dosage form.

Pharmaceutical qualification requirements

Drug manufacturers generally assess:

• Identity and structural characterization
• Molecular-weight distribution
• Viscosity and moisture content
• Microbial limits
• Residual proteins and fermentation impurities
• Heavy metals and elemental impurities
• Residual processing chemicals
• Batch-to-batch uniformity
• Stability under storage conditions
• Compatibility with the active ingredient
• Supplier change-control procedures

The absence of a broad compendial monograph can increase customer qualification time compared with more established excipients such as lactose, microcrystalline cellulose, or HPMC.

What patents protect pullulan formulations and manufacturing methods?

The core pullulan material is an established polysaccharide and is not generally the source of durable exclusivity by itself. Commercial intellectual property is more likely to cover:

• Fermentation organisms and production methods
• Purification and molecular-weight control
• Capsule shell compositions
• Pullulan-HPMC or pullulan-starch blends
• Plasticizer systems
• Oral-film compositions
• Mucoadhesive delivery systems
• Encapsulation of specific active ingredients
• Controlled-release particles
• Manufacturing parameters for capsule and film production

Patent protection is therefore fragmented. A formulation patent may cover a particular active ingredient, dosage form, polymer ratio, or manufacturing process without preventing use of pullulan in unrelated products.

Orange Book and Paragraph IV status

Pullulan itself has no Orange Book listing because it is an excipient rather than an approved active pharmaceutical ingredient. It does not have standalone Hatch-Waxman exclusivity, patent-term extension, or Paragraph IV litigation.

Paragraph IV risk can arise indirectly when pullulan is incorporated into a branded drug product and the relevant product patent claims the dosage form or delivery system. In that situation, the litigation concerns the drug formulation or method of use, not pullulan as a standalone material.

Biosimilar risk is also not directly applicable. Pullulan is not a biologic active ingredient. Its commercial exposure to biosimilars is indirect and arises only when it is used in a delivery system associated with a biologic product.

When does pullulan lose exclusivity?

Pullulan has no single global exclusivity date. The material has been commercially known for decades, so fundamental composition claims are generally not the central barrier to competition. Exclusivity remains possible for newer manufacturing processes, specific grades, capsule technologies, delivery systems, and active-ingredient combinations.

Intellectual-property category	Exclusivity outlook
Basic pullulan composition	Limited standalone exclusivity
Fermentation process	Potentially meaningful where process yields or purity differ
Pharmaceutical-grade specifications	Usually protected through know-how and qualification rather than broad patents
Capsule shell formulation	Potential patent protection for specific blends and performance claims
Oral-film formulation	Potential patent protection around active ingredient and polymer system
Manufacturing equipment and parameters	Often protected as trade secrets or narrow process claims
Finished drug product	Protection depends on product-specific patents and regulatory exclusivity

Trade secrets may matter more than patents in fermentation yield, purification, drying, and quality-control procedures. This increases the value of supplier relationships and makes technical transfer more difficult.

How does pullulan compare with HPMC and gelatin?

Factor	Pullulan	HPMC	Gelatin
Source	Fermentation-derived	Cellulose-derived	Animal-derived collagen
Vegetarian suitability	Yes	Yes	No
Oxygen barrier	Strong	Moderate to strong, grade-dependent	Variable
Cost	Generally high	Moderate to high	Low to moderate
Pharmaceutical adoption	Specialized	Broad	Very broad
Film formation	Strong	Strong	Strong
Qualification history	More limited	Well established	Very established
Main advantage	Barrier performance and plant-based positioning	Broad regulatory and manufacturing acceptance	Cost and market familiarity
Main weakness	Price and limited scale	Moisture and process sensitivity	Animal-origin restrictions

Pullulan is unlikely to replace gelatin or HPMC across the full capsule market. Its better opportunity is selective penetration in premium capsules, oxygen-sensitive products, vegetarian formulations, and specialized oral films.

What generic launch risks exist for pullulan-based products?

Generic launch risk is low at the excipient level and higher at the finished-product level.

A generic manufacturer can usually source an equivalent excipient or develop a different excipient system unless the branded product has narrow formulation, process, or performance claims. The main barriers are:

1. Demonstrating equivalent dissolution and stability.
2. Matching capsule or film mechanical performance.
3. Reproducing oxygen and moisture protection.
4. Establishing supplier consistency.
5. Navigating formulation patents.
6. Validating manufacturing processes at commercial scale.

For a pullulan-based drug, the key litigation risk is not whether pullulan can be purchased. It is whether the generic can avoid claims covering the specific formulation, dosage form, release profile, or manufacturing method.

What is the commercial outlook and financial trajectory for pullulan?

The base-case trajectory is steady expansion from a niche specialty excipient into a broader plant-based delivery-material category.

Period	Expected market condition
Near term	Growth led by nutraceutical capsules, specialty foods, and qualified pharmaceutical applications
Medium term	Increased adoption in oral films, probiotic protection, and high-value encapsulation
Longer term	Margin differentiation between commodity-grade and pharmaceutical-grade products

Revenue growth should outpace volume growth where suppliers shift toward pharmaceutical-grade material and customized systems. Average selling prices can remain higher when customers require regulatory packages, validated supply, and technical support.

The principal downside risks are high cost relative to HPMC, limited pharmaceutical monograph coverage, customer qualification timelines, dependence on a small group of qualified producers, and substitution by improved HPMC or synthetic film-forming systems.

Key Takeaways

• Pullulan is a specialty polysaccharide excipient with applications in capsules, oral films, coatings, and encapsulation.
• The market is small but has a favorable growth profile driven by vegetarian dosage forms, oxygen protection, and plant-based formulation demand.
• Public companies do not separately disclose pullulan revenue, making precise market-share and company-revenue estimates unavailable.
• Hayashibara, part of Nagase Group, is the leading established supplier associated with pharmaceutical-grade pullulan.
• Pharmaceutical-grade pullulan commands a premium because of purification, testing, documentation, and customer qualification requirements.
• Pullulan has no standalone Orange Book, Paragraph IV, or biosimilar exclusivity profile.
• The strongest intellectual-property positions are likely to involve manufacturing processes, capsule compositions, oral films, and active-ingredient-specific delivery systems.
• HPMC and gelatin remain stronger on scale, cost, and regulatory familiarity.
• The best commercial opportunities are premium capsules, oxygen-sensitive products, oral thin films, and specialty encapsulation.
• Financial performance will depend more on grade mix, qualification retention, and technical services than on bulk pullulan volume alone.

FAQs About Pullulan Pharmaceutical Excipient Markets

Is pullulan listed as an inactive ingredient in FDA-approved drugs?

Pullulan may be present in products evaluated through FDA’s inactive-ingredient framework, but its suitability must be assessed for the specific dosage form, route, concentration, and finished product.

Which companies manufacture pharmaceutical-grade pullulan?

Hayashibara, a Nagase Group company, is the most established named supplier. Chinese fermentation manufacturers and regional specialty suppliers also compete, particularly in food, nutraceutical, and price-sensitive applications.

Can pullulan replace gelatin in hard capsules?

Yes. Pullulan can support vegetarian and non-animal capsule systems, but its higher cost, processing requirements, and qualification history limit universal substitution.

Is pullulan suitable for biologic drug delivery?

Pullulan can be used in delivery research and encapsulation systems involving biologics, but it is not itself a biologic active ingredient. Product-specific stability, immunogenicity, sterility, and regulatory requirements determine suitability.

Does pullulan have a USP-NF monograph?

The availability and scope of compendial coverage must be assessed against the current USP-NF edition and the supplier’s specification. In practice, pharmaceutical users rely heavily on supplier qualification packages, internal specifications, and product-specific regulatory assessment.

References

1. Grand View Research. (2024). Pullulan market size, share and trends analysis report by application and segment forecasts, 2024-2030. Grand View Research.
2. Nagase & Co., Ltd. (2024). Integrated report 2024. Tokyo, Japan: Nagase & Co., Ltd.
3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. Center for Drug Evaluation and Research.
4. European Food Safety Authority. (2010). Scientific opinion on the re-evaluation of pullulan (E 1204) as a food additive. EFSA Journal, 8(3), 1532.